BioVie (BIVI) vs Radiopharm Theranostics (RADX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
BioVie (BIVI) has outperformed Radiopharm Theranostics (RADX) over the past year, losing 38.2% versus a loss of 86.1%. Radiopharm Theranostics is the larger company by market cap ($9.9 million vs $8.6 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BIVI | RADX |
|---|---|---|
| Share price | $0.80 | $0.6304 |
| Market cap | $8.58M | $9.90M |
| 1-day change | -12.07% | -9.71% |
| YTD return | -31.03% | -87.92% |
| 1-year return | -38.22% | -86.15% |
| 5-year return | -99.87% | — |
| EPS (TTM) | $-2.85 | $-3.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $3.63M |
| Revenue growth (YoY) | — | +1114.27% |
| Net income (latest FY) | $-22.07M | $-38.34M |
| Gross margin | — | 1.08% |
| Operating margin | — | -1050.63% |
| Net margin | — | -1055.27% |
| 52-week high | $3.79 | $16.25 |
| 52-week low | $0.7515 | $0.63 |
| Distance from 52-week high | -78.89% | -96.12% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +557.50% | +2595.11% |
| Average volume | 568.61K | 55.23K |
| Shares outstanding | 10.72M | 15.70M |
| Employees | 13 | 14 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BIVI has outperformed RADX by 47.9 percentage points over the past year.
About BioVie
BIVI stock →BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 3 for the treatment of life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism.
Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees
About Radiopharm Theranostics
RADX stock →Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic.
Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees
BIVI vs RADX FAQ
Which is bigger, BioVie or Radiopharm Theranostics?
Radiopharm Theranostics (RADX) is larger, with a market capitalization of $9.90M compared with $8.58M for BioVie (BIVI).
Which stock has performed better over the past year, BIVI or RADX?
BIVI returned -38.22% over the past 12 months, compared with -86.15% for RADX (price return, excluding dividends). Past performance does not predict future results.
Are BioVie and Radiopharm Theranostics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.